PMID- 24377572
OWN - NLM
STAT- MEDLINE
DCOM- 20150106
LR  - 20201209
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 14
IP  - 11
DP  - 2014 Jan
TI  - Efficacy and tolerability of adjuvant oral capecitabine plus intravenous 
      oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
PG  - 6585-90
AB  - BACKGROUND: Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) 
      is established as a standard chemotherapeutic regimen, the long term efficacy of 
      adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian 
      colorectal cancer (CRC) patients remains anecdotal. Moreover, uncertainties 
      persist as to whether pharmacogenetic differences in Asian populations preclude 
      equally tolerable and effective administration of these drugs. METHOD: One 
      hundred consecutive patients with resected colorectal cancer received adjuvant 
      XELOX (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 900 mg/m2 twice daily on 
      day 1 to 14 every 3 weeks for 8 cycles) at Queen Mary Hospital, Hong Kong. 
      Endpoints monitored during follow-up were disease-free survival (DFS) and disease 
      recurrence, overall survival (OS) and adverse events (AEs). RESULTS: The median 
      patient age was 56 years, 56% were diagnosed with rectal cancer and 44% with 
      colonic cancer. After a median follow-up of 4.3 years (95% confidence interval, 
      3.2-4.7), 24 recurrences were confirmed including 13 patients who died due to 
      progressive disease. Four-year DFS was 81% in colon cancer patients and 67% in 
      rectal cancer patients (p=0.06 by log-rank test). For the cohort as a whole, OS 
      was 90% at 3 years and 84% at 5 years. Treatment-related AEs led to early 
      withdrawal in four patients. The commonest non-hematological AEs were neuropathy 
      (91%), hand-foot syndrome (49%) and diarrhea (46%), while the commonest grade 3/4 
      AEs were neutropenia (11%) and diarrhea (10%). CONCLUSION: These results confirm 
      the favourable long term survival benefit with good tolerability in using 
      adjuvant XELOX in treating East Asian colorectal cancer patients.
FAU - Chiu, Joanne
AU  - Chiu J
AD  - University Department of Medicine, Queen Mary Hospital, Hong Kong, China E-mail : 
      the@netvigator.com.
FAU - Tang, Vikki
AU  - Tang V
FAU - Leung, Roland
AU  - Leung R
FAU - Wong, Hilda
AU  - Wong H
FAU - Chu, Kin Wah
AU  - Chu KW
FAU - Poon, Jensen
AU  - Poon J
FAU - Epstein, Richard J
AU  - Epstein RJ
FAU - Yau, Thomas
AU  - Yau T
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Oxaloacetates)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
RN  - XELOX
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Capecitabine
MH  - Chemotherapy, Adjuvant
MH  - Colorectal Neoplasms/*drug therapy/mortality/pathology
MH  - Deoxycytidine/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Fluorouracil/*analogs & derivatives/therapeutic use
MH  - Follow-Up Studies
MH  - Hong Kong
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality/pathology
MH  - Neoplasm Staging
MH  - Oxaloacetates
MH  - Prognosis
MH  - Survival Rate
MH  - Time Factors
EDAT- 2014/01/01 06:00
MHDA- 2015/01/07 06:00
CRDT- 2014/01/01 06:00
PHST- 2014/01/01 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2015/01/07 06:00 [medline]
AID - 10.7314/apjcp.2013.14.11.6585 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2014 Jan;14(11):6585-90. doi: 
      10.7314/apjcp.2013.14.11.6585.